High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Exclusion Criteria

• •Any of the following conditions:
• •* congestive heart failure (NYHA \> II)
• •* documented EBV, HBV or HCV infection (only for allogeneic PBSCT)
• •* creatinine clearance \< 60 ml/min
• •* left ventricular ejection fraction \< 40%
• •* bilirubin \> 2 mg/dl
• •Severe opportunistic infection
• •More than 10% of bone marrow involved with lymphoma
• •Between 2 and 5 10\^6 autologous CD34+ cells/kg BW obtained after leukapheresis and CD34 enrichment
• •Women of child.bearing potential not under adequate contraceptive protection
• •Women who are pregnant or breast feeding
• •Known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study
• •Participation in another study with an investigational product within less than one month prior to this study
• •Simultaneous participation in a study with an investigational drug
• •Presence of any disease likely to require procedures altering the schedule of the protocol
• •Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator
• •Patients with limited mental capacity to the extent that he/she cannot provide informed consent or information regarding adverse events of the study medication
• •Patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular disease
• •Patients who have previously been admitted to this study
• •Patients who will not accept transfusions of blood products